Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Apr 28, 2022

BUY
$12.02 - $16.79 $33,656 - $47,012
2,800 Added 10.02%
30,750 $373,000
Q4 2021

Feb 02, 2022

BUY
$9.93 - $15.39 $9,930 - $15,390
1,000 Added 3.71%
27,950 $397,000
Q4 2020

Mar 12, 2021

SELL
$37.09 - $48.97 $48,217 - $63,661
-1,300 Reduced 4.6%
26,950 $1.02 Million
Q3 2020

Oct 29, 2020

BUY
$40.47 - $45.5 $1.14 Million - $1.29 Million
28,250 New
28,250 $1.16 Million
Q4 2019

Feb 04, 2020

SELL
$34.58 - $48.06 $1.01 Million - $1.41 Million
-29,250 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$36.98 - $48.45 $1.15 Million - $1.5 Million
-31,050 Reduced 51.49%
29,250 $1.11 Million
Q2 2019

Aug 01, 2019

BUY
$35.13 - $55.53 $953,779 - $1.51 Million
27,150 Added 81.9%
60,300 $2.69 Million
Q1 2019

May 10, 2019

BUY
$42.83 - $59.91 $256,980 - $359,460
6,000 Added 22.1%
33,150 $2.02 Million
Q4 2018

Feb 12, 2019

SELL
$37.97 - $60.16 $227,820 - $360,960
-6,000 Reduced 18.1%
27,150 $1.19 Million
Q3 2018

Nov 09, 2018

SELL
$56.3 - $67.25 $47,855 - $57,162
-850 Reduced 2.5%
33,150 $0
Q1 2018

May 03, 2018

SELL
$45.35 - $61.65 $530,595 - $721,305
-11,700 Reduced 25.6%
34,000 $1.57 Million
Q3 2017

Nov 06, 2017

BUY
$33.4 - $53.9 $1.53 Million - $2.46 Million
45,700
45,700 $1.86 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $31.9M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Deka Bank Deutsche Girozentrale Portfolio

Follow Deka Bank Deutsche Girozentrale and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.